arimoclomol
Treatment for Niemann-Pick Disease, type C
Orphazyme Announces FDA Acceptance and Priority Review of New Drug Application for Arimoclomol for Niemann-Pick Disease Type C
Copenhagen, Denmark, September 16, 2020 – Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted, with Priority Review, the company’s New Drug Application (NDA) for arimoclomol for the treatment of NPC.
The FDA grants Priority Review to applications for potential therapies that, if approved, could offer a significant improvement in safety or effectiveness, diagnosis, or prevention of serious conditions. This designation shortens the review period from the standard 10 months to six months from the acceptance of the NDA. The FDA has set a target action date of March 17, 2021 under the Prescription Drug User Fee Act (PDUFA) and has indicated that it does not currently plan to hold an advisory committee meeting to discuss the application.
Kim Stratton, Chief Executive Officer, Orphazyme, said, “The filing acceptance marks a significant milestone in our journey towards our first potential approval of arimoclomol for NPC, a devastating and often fatal disease for which there is no approved therapy in the U.S. We look forward to collaborating with the FDA as they complete their review of this NDA to address the unmet medical need in NPC, and meanwhile are working to expand our U.S. activities in preparation for potential commercial availability next year.”
“Acceptance of the arimoclomol filing by the FDA is another major step forward in the effort to bring a treatment to people affected by Niemann-Pick disease Type C and is a reflection of the commitment of the entire community coming together to support promising research,” said Joslyn Crowe, Executive Director of the National Niemann-Pick Disease Foundation.
Arimoclomol has been granted FDA Fast Track and Breakthrough Therapy Designations for NPC, as well as Orphan Drug and Rare Pediatric Disease Designations. Orphazyme expects to file a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for arimoclomol in NPC in H2 2020.
Source: Orphazyme A/S
Posted: September 2020
Related Articles
More News Resources
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Related Post
Feb
10 Health Benefits of Eating Eggs for Breakfast
Might it be said that you are fed up with having exactly the same thing for breakfast consistently? Does your morning meal leave you feeling hungry simply a brief time frame after you eat? Then eating a couple of eggs.
Read MoreFeb
Study Reveals Extent of Undiagnosed Cancer Cases Due to COVID-19 Pandemic
North of 134,000 disease cases went undiscovered in the U.S. during the initial 10 months of the Coronavirus pandemic, as per another College of Kentucky Markey Disease Center review. The report distributed in JAMA Oncology gives the principal assessments of.
Read MoreFeb
Another COVID Toll: Over 134,000 Undiagnosed Cancers During Height of Pandemic
In excess of 134,000 diseases could have gone undiscovered during the initial 10 months of the Coronavirus pandemic, as per an investigation of public patterns in malignant growth rate. Yearly disease occurrence fell practically 30% shy of the normal rate from.
Read MoreFeb
Top 10 Health Benefits of Eucalyptus
Eucalyptus is an evergreen tree local to Australia. Throughout the long term, eucalyptus leaves and oils have been consumed and made into prescription for different medical issue for people all over the planet. During the eighteenth and nineteenth hundreds of.
Read More